BBT Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

BBT Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,143	Closed	-$234K	–	146
2015 Q3	$234K	Sell	4,143 -9,382	-69%	-$608K	0.02%	154
2015 Q2	$799K	Sell	13,525 -2,670	-16%	-$165K	0.07%	131
2015 Q1	$1.01M	Buy	+16,195	New	+$942K	0.1%	126
2014 Q2	–	Sell	-50,000	Closed	-$2.64M	–	272
2014 Q1	$2.64M	Sell	50,000 -18,523	-27%	-$856K	0.12%	192
2013 Q4	$2.75M	Buy	+68,523	New	+$2.7M	0.13%	185

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BBT Capital Management's TEVA Position: Q4 2015 in Review

BBT Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 4,143 shares — an estimated $234K sold.

BBT Capital Management first reported a position in TEVA in Q4 2013 and held it in 5 quarters. The position peaked at $2.75M in Q4 2013. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

BBT Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
BBT Capital Management sold 4,143 Teva Pharmaceuticals shares in Q4 2015, an estimated $234K.
BBT Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 5 quarters.
BBT Capital Management's Teva Pharmaceuticals position peaked at $2.75M in Q4 2013.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on BBT Capital Management's 13F filing for Q4 2015, filed 10 Feb 2016.